<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103527</url>
  </required_header>
  <id_info>
    <org_study_id>DRG-S for Knee OA</org_study_id>
    <nct_id>NCT05103527</nct_id>
  </id_info>
  <brief_title>Dorsal Root Ganglion Stimulation for the Treatment of Arthritic Knee Pain</brief_title>
  <official_title>Dorsal Root Ganglion Stimulation Outcomes for the Treatment of Mechanical Knee Pain Among Patients With Osteoarthritis of the Surgical and Non-surgical Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kenneth B Chapman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spine and Pain Institute of New York</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dorsal root ganglion stimulation (DRG-S) may be able to treat mechanical pain caused by&#xD;
      tissue injury or damage such as trauma or arthritis in addition to pain caused by nerve&#xD;
      dysfunction or injury. The purpose of this study is to determine if dorsal root ganglion&#xD;
      stimulation (DRG-S) can effectively treat arthritic pain of the knee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dorsal root ganglion stimulation (DRG-S) is a novel form of neuromodulation used to treat&#xD;
      chronic neuropathic pain of the groin and lower extremities related to complex regional pain&#xD;
      syndrome type I or II (causalgia). DRG-S has shown promise in treating traditionally mixed&#xD;
      neuropathic and mechanical pain syndromes such as axial low back pain, suggesting DRG-S may&#xD;
      be able to treat mechanical pain in addition to neuropathic pain. Additionally, in a rodent&#xD;
      model of osteoarthritis of the knee, DRG-S alleviated pain related behavior in rats.&#xD;
&#xD;
      This open label feasibility study seeks to evaluate if dorsal root ganglion stimulation with&#xD;
      Abbott's Proclaim Dorsal Root Ganglion Neurostimulator System can effectively treat&#xD;
      osteoarthritis of the knee. Patients with either osteoarthritis of the non-operated knee or&#xD;
      osteoarthritis of the surgically repaired knee will be trialed for one week with dorsal root&#xD;
      ganglion stimulation to determine if they positively respond with 50% or greater pain relief.&#xD;
      For those patients that have a successful trial, they will be implanted with a permanent&#xD;
      stimulation device system and followed for one year post implant to measure knee pain,&#xD;
      function and disability, and other related outcomes with sustained DRG-S therapy.&#xD;
&#xD;
      Patients will be seen and evaluated prior to DRG-S trial, and for those that receive&#xD;
      permanent implants, re-evaluated at 1, 3, 6, 9 and 12 months after implant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will undergo one week DRG-S trial, and for those that respond as defined by 50% or greater pain relief, proceed to DRG-S permanent device system implant</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NRS pain scores</measure>
    <time_frame>3 months post-implant</time_frame>
    <description>Subject's Numeric Rating Scale (NRS) score for knee pain being treated by DRG simulation for 3 months of designated treatment on a 22 point scale from 0-10 in 0.5 increments with 0 being no pain to 10 being the worse imaginable pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NRS pain scores</measure>
    <time_frame>1-, 6-, 9-, and 12 months post-implant</time_frame>
    <description>Subject's Numeric Rating Scale (NRS) score for knee pain being treated by DRG on a 22 point scale from 0-10 in 0.5 increments with 0 being no pain to 10 being the worse imaginable pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and McMaster Universities Arthritis Index (WOMAC) for knee pain patients</measure>
    <time_frame>1-, 3-, 6-, 9-, and 12 months post-implant</time_frame>
    <description>At each study visit, subjects will complete WOMAC survey which assesses pain, stiffness, and function in patients with OA of the knee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Quality of Life 5 Dimension (EQ-5D)</measure>
    <time_frame>1-, 3-, 6-, 9-, and 12 months post-implant</time_frame>
    <description>At each study visit, subjects will complete EQ-5D survey which assesses health-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36 Mental Component Summary (SF-36 MCS)</measure>
    <time_frame>1-, 3-, 6-, 9-, and 12 months post-implant</time_frame>
    <description>At each study visit, subjects will complete SF-36 MCS survey which assesses mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Disability Index (PDI)</measure>
    <time_frame>1-, 3-, 6-, 9-, and 12 months post-implant</time_frame>
    <description>At each study visit, subjects will complete PDI survey which assesses pain-related disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC)</measure>
    <time_frame>1-, 3-, 6-, 9-, and 12 months post-implant</time_frame>
    <description>At each study visit, subjects will complete PDI survey which assesses patient's belief about the efficacy of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Dosage</measure>
    <time_frame>1-, 3-, 6-, 9-, and 12 months post-implant</time_frame>
    <description>Patient's dose of narcotic analgesics measured in morphine milligram equivalents (MME) and non-narcotic analgesics and dosages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed Up and Go (TUG)</measure>
    <time_frame>1-, 3-, 6-, 9-, and 12 months post-implant</time_frame>
    <description>Video recordings of motor task exams will be used to measure TUG, a performance-based measure of functional mobility which measures the time for subject to rise from a chair, walk three meters, turn around, return to the chair, and sit down.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Range of Motion (ROM)</measure>
    <time_frame>1-, 3-, 6-, 9-, and 12 months post-implant</time_frame>
    <description>Video recordings of motor task exams will be used to measure ROM of the index knee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of molecular biomarkers</measure>
    <time_frame>3-, 6-, and 12-months post-implant</time_frame>
    <description>Serum concentrations of molecular biomarkers related to knee OA including but not limited to C-telopeptide of crosslinked collagen type I and type II (CTX-I and CTX-II)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kellgren-Lawrence System for Classification of Osteoarthritis</measure>
    <time_frame>6- and 12-months post-implant</time_frame>
    <description>Radiologic classification of subject's knee x-ray to grade progression/severity of osteoarthritis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 12 months post-implant</time_frame>
    <description>All complications of DRG-S trial, implant, and stimulation therapy will be reported</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <condition>Knee Pain Chronic</condition>
  <condition>Knee Arthritis</condition>
  <condition>Knee Arthropathy</condition>
  <arm_group>
    <arm_group_label>Non-operated Knee Osteoarthritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DRG-S for knee osteoarthritis patients with no history of knee surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgically Repaired Knee Osteoarthritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DRG-S for knee osteoarthritis patients with history of surgical repair of the knee</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dorsal Root Ganglion Stimulation</intervention_name>
    <description>Stimulation at L2, L3, L4 and S1 spinal levels</description>
    <arm_group_label>Non-operated Knee Osteoarthritis</arm_group_label>
    <arm_group_label>Surgically Repaired Knee Osteoarthritis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 21 years old&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Primary complaint of chronic knee pain for at least 1 year that interferes with&#xD;
             functional activities&#xD;
&#xD;
          -  Current pain score on visual analog scale (VAS) intensity ≥60 mm&#xD;
&#xD;
          -  One of two groups: 1) Non-operated knee pain patients who want to pursue alternative&#xD;
             therapies and delay surgery or are not candidates for knee arthroplasty based on age,&#xD;
             frailty, non-operable condition, or poor outcome with other side arthroplasty, or 2)&#xD;
             Post traumatic knee pain patients with history of surgical repair (such as meniscal or&#xD;
             ligament repair).&#xD;
&#xD;
          -  Radiologic confirmation (x-ray/MRI/CT) of Kellgren-Lawrence OA grade of 2 (mild) or 3&#xD;
             (moderate) noted within 6 months for the index knee&#xD;
&#xD;
          -  Continued pain in the target knee despite at least 3 months of conservative treatments&#xD;
             with documented failure of physical therapy and standard conservative therapy,&#xD;
             including trials of at least two different classes of analgesic medication&#xD;
&#xD;
          -  Failure of one or more prior interventional pain procedures such intraarticular&#xD;
             corticosteroid or hyaluronidase knee injections, cooled radiofrequency ablation&#xD;
             therapy, or regenerative medicine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  Douleur neuropathique 4 (DN4) score ≥4&#xD;
&#xD;
          -  Receiving opioid analgesic medication at a dose of ≥90 mg oral morphine equivalents&#xD;
&#xD;
          -  Workers' compensation or no-fault insurance&#xD;
&#xD;
          -  Signs or symptoms of active infection in the index knee joint&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  BMI &gt;45&#xD;
&#xD;
          -  Presence of any contraindication for DRG stimulation, including neurological, medical,&#xD;
             psychiatric, or social conditions.&#xD;
&#xD;
          -  Widespread pain conditions like fibromyalgia&#xD;
&#xD;
          -  Autoimmune/Inflammatory arthritic conditions such as Rheumatoid and psoriatic&#xD;
             arthritis and other allied disorders (sjogren, felty, inflammatory bowl disease etc)&#xD;
&#xD;
          -  Collagen diseases (systemic lupus erythematosus, Scleroderma, etc)&#xD;
&#xD;
          -  Infectious arthritis&#xD;
&#xD;
          -  Evidence of prespecified joint safety conditions (eg, rapidly progressive OA,&#xD;
             subchondral insufficiency fracture, osteonecrosis, pathologic fracture) in the index&#xD;
             knee on screening radiographs&#xD;
&#xD;
          -  Scheduled for or anticipating any surgery during the trial period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kenneth B Chapman, MD</last_name>
    <phone>7186673577</phone>
    <email>chapmanken@spinepainny.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tariq a Yousef, MD</last_name>
    <phone>7186673577</phone>
    <email>tyousef@spinepainny.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Spine and Pain Institute of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ahmad Amireh, BS</last_name>
      <phone>718-667-3577</phone>
      <email>tyousef@spinepainny.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yu G, Segel I, Zhang Z, Hogan QH, Pan B. Dorsal Root Ganglion Stimulation Alleviates Pain-related Behaviors in Rats with Nerve Injury and Osteoarthritis. Anesthesiology. 2020 Aug;133(2):408-425. doi: 10.1097/ALN.0000000000003348.</citation>
    <PMID>32433276</PMID>
  </reference>
  <reference>
    <citation>Bjerre-Bastos JJ, Bay-Jensen A-C, Karsdal MA, Byrjalsen I, Andersen JR, Riis BJ, et al. Biomarkers of bone and cartilage turnover CTX-I and CTX-II predict total joint replacements in osteoarthritis. Osteoarthr Cartil [Internet]. 2019;27(2019):S31-2. Available from: https://doi.org/10.1016/j.joca.2019.02.046</citation>
  </reference>
  <reference>
    <citation>Convill JG, Tawy GF, Freemont AJ, Biant LC. Clinically Relevant Molecular Biomarkers for Use in Human Knee Osteoarthritis: A Systematic Review. Cartilage. 2020 Jul 17:1947603520941239. doi: 10.1177/1947603520941239. [Epub ahead of print]</citation>
    <PMID>32680434</PMID>
  </reference>
  <reference>
    <citation>Adhikary SD, Liu WM, Memtsoudis SG, Davis CM 3rd, Liu J. Body Mass Index More Than 45 kg/m(2) as a Cutoff Point Is Associated With Dramatically Increased Postoperative Complications in Total Knee Arthroplasty and Total Hip Arthroplasty. J Arthroplasty. 2016 Apr;31(4):749-53. doi: 10.1016/j.arth.2015.10.042. Epub 2015 Nov 10.</citation>
    <PMID>26652477</PMID>
  </reference>
  <reference>
    <citation>van Bussel CM, Stronks DL, Huygen FJPM. Dorsal Column Stimulation vs. Dorsal Root Ganglion Stimulation for Complex Regional Pain Syndrome Confined to the Knee: Patients' Preference Following the Trial Period. Pain Pract. 2018 Jan;18(1):87-93. doi: 10.1111/papr.12573. Epub 2017 May 4.</citation>
    <PMID>28334499</PMID>
  </reference>
  <reference>
    <citation>Kallewaard JW, Edelbroek C, Terheggen M, Raza A, Geurts JW. A Prospective Study of Dorsal Root Ganglion Stimulation for Non-Operated Discogenic Low Back Pain. Neuromodulation. 2020 Feb;23(2):196-202. doi: 10.1111/ner.12937. Epub 2019 Mar 1.</citation>
    <PMID>30821901</PMID>
  </reference>
  <reference>
    <citation>Huygen F, Liem L, Cusack W, Kramer J. Stimulation of the L2-L3 Dorsal Root Ganglia Induces Effective Pain Relief in the Low Back. Pain Pract. 2018 Feb;18(2):205-213. doi: 10.1111/papr.12591. Epub 2017 Dec 6.</citation>
    <PMID>28486758</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Spine and Pain Institute of New York</investigator_affiliation>
    <investigator_full_name>Kenneth B Chapman</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Dorsal Root Ganglion Stimulation</keyword>
  <keyword>knee pain</keyword>
  <keyword>knee arthritis</keyword>
  <keyword>osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganglion Cysts</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

